title: Lafora disease.
abstract: Lafora disease (LD) is an autosomal recessive disorder characterized by seizures and progressive neurologic deterioration, and is usually fatal within 10 years of onset. LD is a member of the family of progressive myoclonic epilepsies, which are a heterogeneous group of disorders characterized by myoclonic epilepsy, developmental regression, and associated neurologic symptoms. The following is a report and discussion of a 20-year-old man with no relevant past medical history until the age of 16 years when he had his first generalized tonic-clonic seizure. At a recent medical evaluation, he reported having clusters of generalized tonic-clonic seizure activity 2 to 3 times per week, had recently developed status epilepticus, and was having progressive impairment of cognitive function. The unique clinical elements of LD, including later onset of disease, the excellent initial response to anticonvulsants, and the neurophysiologic clues to the diagnosis are discussed and detailed in relation to this man. Additional research is required to discover a third, unknown locus for LD and to further elucidate the features of the laforin and malin complex-associated pathway. No preventative or curative treatment is currently available for LD and treatment focuses on palliation.
authors.affiliation: New York University Comprehensive Epilepsy Center, Department of Neurology, New York University School of Medicine, New York, NY, USA.
authors.forename: Deepak
authors.initials: D
authors.lastname: Madhavan
authors.forename: Ruben I
authors.initials: RI
authors.lastname: Kuzniecky
mesh_terms: D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D000927:Anticonvulsants / Q000627:therapeutic use; D004569:Electroencephalography; D006801:Humans; D020192:Lafora Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male
chemical_list: D000927:Anticonvulsants